Genmab — April 2018
-
Bulder. Jeg har konsensus fra en Deutsche Bank update. Deutsche Bank har forøvrigt selv 425.
-
Det har sikkert været omtalt, da ik´ke meget undgår nogens opmærksomhed her, men hvis nu ikke, så er HuMax
-IL8 (BMS-986253) startet op igen i form af "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers" https://clinicaltrials.gov/ct2/show/NCT03400332?term=BMS-986253&rank=1 -
-
BMS har før kørt et fase 1 studie i humax il8 kan jeg se https://www.clinicaltrials.gov/ct2/show/NCT02536469?term=humax+il8&rank=1 - og vil nu åbenbart prøve det af i kombi med nivo. Det må vel udløse en milestone mere.
-
BMS købte vel i sin tid Cormorant hovedsageligt pga Humax il8? https://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquires-cormorant-pharmaceuticals
-
Skulle man være modig og supplere lidt inden q1 salgstallene i morgen?
-
Hælder mest til tallene skuffer og vi falder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind